UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells

Figure 1

Aberrant activation of UBE2C and ZEB1/2 in lung cancer cells and downregulated by treatment with DDP. (a) Gel-based RT-PCR, immunoblotting with densitometric quantitation and qPCR demonstrating elevated mRNA and protein expression of UBE2C in human lung cancer cells compared with their normal control cell HBEC. (b) A549 cells were incubated with DDP at various concentrations for 24, 48, and 72 h (left panel) and various times at 3, 6 and 9 μg/ml (right panel). Then cell viability was assessed (%). (c–e) DDP dose-dependently repressed UBE2C and ZEB1/2 in mRNA and protein level in A549 and H1299 cells analyzed by RT-PCR (c), Western blot (d) and qPCR (e) assay. (f–h) DDP time-dependently repressed UBE2C and ZEB1/2 in mRNA and protein level in A549 and H1299 cells analyzed by RT-PCR (f), Western blot (g) and qPCR (h) assay. (i) Survival rates of A549/DDP, H1299/DDP and their control cells treated with DDP at 6 μg/ml for 48 h. (j–l) The mRNA and protein expression levels were analyzed by RT-PCR (j), Western blot (k) and qPCR (l) assay. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. p<0.05; p<0.01 versus control group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)